Calithera Biosciences Inc (CALA)

Sector:
HEALTH CARE
Industry:
PHARMACEUTICALS
SIC:
PHARMACEUTICAL PREPARATIONS
CEO:
Susan M. Molineaux
Employees:
79
343 OYSTER POINT BLVD #200, SOUTH SAN FRANCISCO, CA 94080
650-870-1000

Calithera Biosciences, Inc. is a clinical-stage pharmaceutical company, which focuses on discovering and developing novel small molecule drugs directed against tumor metaboli® and tumor immunology targets for the treatment of cancer. The company was founded by James A. Wells and Susan M. Molineaux on March 9, 2010 and is headquartered in South San Francisco, CA.

Data derived from most recent annual or quarterly report
Market Cap 215.038 Million Shares Outstanding74.926 Million Avg 30-day Volume 1.839 Million
P/E Ratio0.0 Dividend Yield0.0 EPS
Price to Revenue4.0291 Debt to Equity0.0 EBITDA-108.221 Million
Price to Book Value0.0 Operating Margin-1112.7385 Enterprise Value35.322 Million
Current Ratio4.156 EPS Growth-0.207 Quick Ratio3.938
1 Yr BETA 9.3202 52-week High/Low 4.99 / 0.15 Profit Margin-1113.1077
Operating Cash Flow Growth23.9486 Altman Z-Score-18.2931 Free Cash Flow to Firm -77.539 Million
Earnings Report2022-08-04
View SEC Filings from CALA instead.

View recent insider trading info

Calithera Biosciences Inc YCharts
Yahoo! Finance finviz
SEC Web Site SEC DEF 14A Filings

Funds Holding CALA (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
Click for Additional Filters
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding CALA BETA

Active Schedule 13D and 13G filings

Please sign in first

Recent Filings

Financial Reporting

Ownership

  • 4: filed on 2022-06-03 by JONES SUZY
  • 4: filed on 2022-06-03 by PAKIANATHAN DEEPIKA
  • 4: filed on 2022-06-03 by GARLAND J. SCOTT
  • 4: filed on 2022-06-03 by AGARWAL SUNIL
  • 4: filed on 2022-06-03 by WISE BLAKE
  • 4: filed on 2022-06-03 by ORFORD KEITH
  • 4: filed on 2022-06-03 by WOLFF HENRY WARD
  • 3: filed on 2022-04-21 by MILLENNIUM PHARMACEUTICALS INC
  • 4: filed on 2022-01-27 by MOLINEAUX SUSAN
  • 4: filed on 2022-01-27 by WONG STEPHANIE

    • Events (8k)

  • 8-K: filed on 2022-06-14:
    Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-05-23:
    Item 1.01: Entry into a Material Definitive Agreement
    Item 3.03: Material Modifications to Rights of Security Holders
    Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-05-10:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-04-12:
    Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
  • 8-K: filed on 2022-03-31:
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-03-31:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2021-12-30:
    Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
  • 8-K: filed on 2021-11-09:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2021-11-05:
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
    Item 7.01: Regulation FD Disclosure
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2021-10-19:
    Item 1.01: Entry into a Material Definitive Agreement
    Item 2.02: Results of Operations and Financial Condition
    Item 3.02: Unregistered Sales of Equity Securities
    Item 3.03: Material Modifications to Rights of Security Holders
    Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
    Item 7.01: Regulation FD Disclosure
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits

    • Proxy

    Prospectus

    All

    Open Market Buys/Sells Last 60 Days

    Open Market Buys (P)

    none

    Open Market Sells (S)

    none

    Exercise Derivative Conversion (M)

    none

    Current/Former Insiders

    Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

    PAKIANATHAN DEEPIKA

    • Director
    		 20,000 2022-06-01 1

    WOLFF HENRY WARD

    • Director
    		 20,000 2022-06-01 1

    GARLAND J. SCOTT

    • Director
    		 20,000 2022-06-01 1

    AGARWAL SUNIL

    • Director
    		 20,000 2022-06-01 1

    WISE BLAKE

    • Director
    		 20,000 2022-06-01 1

    ORFORD KEITH

    • Director
    		 20,000 2022-06-01 5

    JONES SUZY

    • Director
    		 20,000 2022-06-01 1

    MOLINEAUX SUSAN PRESIDENT & CEO

    • Officer
    • Director
    		 597,475 2022-01-25 2

    WONG STEPHANIE SEE REMARKS

    • Officer
    		 215,000 2022-01-25 5

    RAY SUMITA SEE REMARKS

    • Officer
    		 165,000 2022-01-25 3

    SJOGREN ERIC SR. VP, DRUG DISCOVERY

    • Officer
    		 165,000 2022-01-25 5

    MOLINEAUX CHRISTOPHER SR. VP, DEVELOPMENT

    • Officer
    		 165,000 2022-01-25 4

    PARLATI FRANCESCO SR. VP, RESEARCH

    • Officer
    		 165,000 2022-01-25 5

    KURIAKOSE EMIL CHIEF MEDICAL OFFICER

    • Officer
    		 215,000 2022-01-25 5

    DRACHMAN JONATHAN G

    • Director
    		 200,000 2021-11-10 1

    TAKEDA PHARMACEUTICAL CO LTD

    MILLENNIUM PHARMACEUTICALS INC

    • 10% Owner
    		 0 2021-10-18 1

    GEORGE JEAN

    • Director
    		 20,000 2021-06-11 0

    HECHT CURTIS CHIEF BUSINESS OFFICER

    • Officer
    		 92,321 2021-01-20 0

    BVF PARTNERS L P/IL

    BIOTECHNOLOGY VALUE FUND L P

    BIOTECHNOLOGY VALUE FUND II LP

    BIOTECHNOLOGY VALUE TRADING FUND OS LP

    BVF PARTNERS OS LTD.

    BVF INC/IL

    LAMPERT MARK N

    • 10% Owner
    • SEE EXPLANATION OF RESPONSESSEE EXPLANATION OF RESPONSESSEE EXPLANATION OF RESPONSESSEE EXPLANATION OF RESPONSES
    		No longer subject to file 2020-05-21 0

    ADAGE CAPITAL PARTNERS GP, L.L.C.

    ADAGE CAPITAL PARTNERS, L.P.

    ADAGE CAPITAL ADVISORS, L.L.C.

    ATCHINSON ROBERT

    GROSS PHILLIP

    • 10% Owner
    		 No longer subject to file 2017-09-26 0

    MORGENTHALER VENTURE PARTNERS IX LP

    • 10% Owner
    		 No longer subject to file 2017-06-01 0

    WADDILL WILLIAM D. SR. VP & CFO

    • Officer
    		 0 2016-11-29 0

    BENNETT MARK K SR. VP, RESEARCH

    • Officer
    		 0 2016-11-29 0

    DELPHI MANAGEMENT PARTNERS VIII, L.L.C.

    DELPHI VENTURES VIII LP

    DELPHI BIOINVESTMENTS VIII LP

    ROEDER DOUGLAS A

    DOUGLASS DAVID L

    BOCHNOWSKI JAMES J

    PAKIANATHAN DEEPIKA

    • Director
    • 10% Owner
    		 2,426,702 2014-10-07 0

    CHRISTOFFERSEN RALPH E

    • Director
    • 10% Owner
    		 2,161,915 2014-10-07 0

    ADVANCED TECHNOLOGY VENTURES VIII LP

    ATV ASSOCIATES VIII, L.L.C.

    • 10% Owner
    		 2,110,082 2014-10-07 0

    Insider Transactions Last 60 Days

    Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
    Disposed    		 Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days

    PAKIANATHAN DEEPIKA - Director

    		2022-06-03 16:05:40 -0400 2022-06-01 A 20,000 a 20,000 direct

    AGARWAL SUNIL - Director

    		2022-06-03 16:05:34 -0400 2022-06-01 A 20,000 a 20,000 direct

    GARLAND J. SCOTT - Director

    		2022-06-03 16:05:34 -0400 2022-06-01 A 20,000 a 20,000 direct

    WISE BLAKE - Director

    		2022-06-03 16:05:26 -0400 2022-06-01 A 20,000 a 20,000 direct

    ORFORD KEITH - Director

    		2022-06-03 16:05:20 -0400 2022-06-01 A 20,000 a 20,000 direct

    WOLFF HENRY WARD - Director

    		2022-06-03 16:05:18 -0400 2022-06-01 A 20,000 a 20,000 direct

    JONES SUZY - Director

    		2022-06-03 16:05:47 -0400 2022-06-01 A 20,000 a 20,000 direct

    * -

    Transaction Code Definitions
    Code Definition
    A Grant, award or other acquisition pursuant to Rule 16b-3(d)
    C Conversion of derivative security
    D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
    E Expiration of short derivative position
    F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
    G Bona fide gift
    H Expiration (or cancellation) of long derivative position with value received
    I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
    J Other acquisition or disposition
    L Small acquisition under Rule 16a-6
    M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
    O Exercise of out-of-the-money derivative security
    P Open market or private purchase of non-derivative or derivative security
    S Open market or private sale of non-derivative or derivative security
    U Disposition pursuant to a tender of shares in a change of control transaction
    W Acquisition or disposition by will or the laws of descent and distribution
    X Exercise of in-the-money or at-the-money derivative security
    Z Deposit into or withdrawal from voting trust

    IBR Securities Loan Availability

    Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

    Security Date/Time Rebate Rate Fee Rate Shares Available
    CALITHERA BIOSCIENCES INC CALA 2022-06-28 22:15:04 UTC -17.3924 18.9624 150000
    CALITHERA BIOSCIENCES INC CALA 2022-06-28 21:45:03 UTC -17.6649 19.2349 150000
    CALITHERA BIOSCIENCES INC CALA 2022-06-28 21:15:03 UTC -17.6649 19.2349 150000
    CALITHERA BIOSCIENCES INC CALA 2022-06-28 20:45:03 UTC -17.6649 19.2349 150000
    CALITHERA BIOSCIENCES INC CALA 2022-06-28 20:15:04 UTC -17.6649 19.2349 150000
    CALITHERA BIOSCIENCES INC CALA 2022-06-28 19:45:03 UTC -17.6649 19.2349 150000
    CALITHERA BIOSCIENCES INC CALA 2022-06-28 19:15:03 UTC -17.6649 19.2349 150000
    CALITHERA BIOSCIENCES INC CALA 2022-06-28 18:45:03 UTC -17.6649 19.2349 150000
    CALITHERA BIOSCIENCES INC CALA 2022-06-28 18:15:04 UTC -17.6649 19.2349 150000
    CALITHERA BIOSCIENCES INC CALA 2022-06-28 17:45:03 UTC -17.6649 19.2349 90000
    CALITHERA BIOSCIENCES INC CALA 2022-06-28 17:15:03 UTC -17.6649 19.2349 90000
    CALITHERA BIOSCIENCES INC CALA 2022-06-28 16:45:06 UTC -19.2905 20.8605 90000
    CALITHERA BIOSCIENCES INC CALA 2022-06-28 16:15:03 UTC -19.2905 20.8605 90000
    CALITHERA BIOSCIENCES INC CALA 2022-06-28 15:45:03 UTC -19.2905 20.8605 90000
    CALITHERA BIOSCIENCES INC CALA 2022-06-28 15:15:03 UTC -19.2905 20.8605 90000
    CALITHERA BIOSCIENCES INC CALA 2022-06-28 14:45:03 UTC -20.54 22.11 90000
    CALITHERA BIOSCIENCES INC CALA 2022-06-28 14:15:04 UTC -20.54 22.11 90000
    CALITHERA BIOSCIENCES INC CALA 2022-06-28 13:45:03 UTC -15.8727 17.4427 90000
    CALITHERA BIOSCIENCES INC CALA 2022-06-28 13:15:03 UTC -15.8727 17.4427 90000
    CALITHERA BIOSCIENCES INC CALA 2022-06-28 12:45:03 UTC -15.8727 17.4427 90000

    Current Active Short Positions

    Holder Issuer Net Short Position Position Date Origin

    Elevate your investments